# A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

> **NCT07491497** · PHASE1,PHASE2 · RECRUITING · sponsor: **TRIANA Biomedicines, Inc.** · enrollment: 160 (estimated)

## Conditions studied

- ALK-positive NSCLC
- ALK-Positive Lung Cancer
- ALK-positive Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TRI-611

## Key facts

- **NCT ID:** NCT07491497
- **Lead sponsor:** TRIANA Biomedicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-11
- **Primary completion:** 2029-05-31
- **Final completion:** 2034-01-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07491497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07491497, "A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07491497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*